McKesson Valuation
Is MCK * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MCK * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MCK * (MX$8870.63) is trading below our estimate of fair value (MX$11556.88)
Significantly Below Fair Value: MCK * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MCK *?
Other financial metrics that can be useful for relative valuation.
What is MCK *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$70.36b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.3x |
Enterprise Value/EBITDA | 17.8x |
PEG Ratio | 2.7x |
Price to Earnings Ratio vs Peers
How does MCK *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 23.6x | ||
COR Cencora | 25.4x | 7.7% | US$47.4b |
CAH Cardinal Health | 39.3x | 16.2% | US$25.1b |
HSIC Henry Schein | 22.6x | 18.4% | US$9.4b |
1099 Sinopharm Group | 6.9x | 6.8% | HK$67.4b |
MCK * McKesson | 23.5x | 8.7% | Mex$70.4b |
Price-To-Earnings vs Peers: MCK * is good value based on its Price-To-Earnings Ratio (23.5x) compared to the peer average (23.6x).
Price to Earnings Ratio vs Industry
How does MCK *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: MCK * is expensive based on its Price-To-Earnings Ratio (23.5x) compared to the Global Healthcare industry average (21.8x).
Price to Earnings Ratio vs Fair Ratio
What is MCK *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 23.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MCK *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$9,553.42 0% | 8.9% | Mex$10,585.94 | Mex$7,000.38 | n/a | 17 |
Apr ’25 | Mex$8,870.63 | Mex$9,238.57 +4.1% | 8.6% | Mex$10,463.68 | Mex$6,919.53 | n/a | 17 |
Mar ’25 | Mex$8,871.41 | Mex$9,264.96 +4.4% | 8.1% | Mex$10,256.46 | Mex$7,008.58 | n/a | 17 |
Feb ’25 | n/a | Mex$8,796.78 0% | 8.3% | Mex$9,713.49 | Mex$6,889.00 | n/a | 16 |
Jan ’25 | n/a | Mex$8,600.81 0% | 7.9% | Mex$9,688.67 | Mex$6,883.60 | n/a | 14 |
Dec ’24 | n/a | Mex$8,413.09 0% | 7.2% | Mex$9,067.13 | Mex$6,843.12 | n/a | 13 |
Nov ’24 | n/a | Mex$8,677.88 0% | 7.5% | Mex$9,465.65 | Mex$7,121.77 | n/a | 13 |
Oct ’24 | n/a | Mex$8,121.72 0% | 6.4% | Mex$8,734.31 | Mex$6,764.81 | n/a | 13 |
Sep ’24 | n/a | Mex$8,078.47 0% | 6.2% | Mex$8,673.72 | Mex$6,717.88 | n/a | 14 |
Aug ’24 | n/a | Mex$7,516.04 0% | 7.2% | Mex$8,340.70 | Mex$6,255.53 | n/a | 14 |
Jul ’24 | Mex$7,050.03 | Mex$7,602.09 +7.8% | 7.7% | Mex$8,559.75 | Mex$6,419.81 | n/a | 15 |
Jun ’24 | Mex$6,864.91 | Mex$7,650.86 +11.4% | 8.3% | Mex$8,631.83 | Mex$6,117.87 | n/a | 15 |
May ’24 | Mex$6,543.00 | Mex$7,581.10 +15.9% | 7.0% | Mex$8,180.85 | Mex$6,257.01 | n/a | 14 |
Apr ’24 | n/a | Mex$7,606.10 0% | 6.6% | Mex$8,110.08 | Mex$6,271.80 | Mex$8,870.63 | 14 |
Mar ’24 | Mex$6,620.00 | Mex$7,864.77 +18.8% | 6.6% | Mex$8,393.00 | Mex$6,490.58 | Mex$8,871.41 | 14 |
Feb ’24 | Mex$6,963.53 | Mex$7,948.07 +14.1% | 6.8% | Mex$8,661.57 | Mex$6,552.67 | n/a | 14 |
Jan ’24 | n/a | Mex$8,098.23 0% | 6.4% | Mex$8,735.36 | Mex$6,755.34 | n/a | 14 |
Dec ’23 | Mex$7,343.00 | Mex$8,016.31 +9.2% | 7.2% | Mex$8,655.48 | Mex$6,462.76 | n/a | 13 |
Nov ’23 | Mex$7,549.00 | Mex$7,710.94 +2.1% | 8.4% | Mex$8,453.44 | Mex$5,955.38 | n/a | 13 |
Oct ’23 | Mex$7,050.00 | Mex$7,736.54 +9.7% | 8.2% | Mex$8,498.45 | Mex$5,987.09 | n/a | 13 |
Sep ’23 | n/a | Mex$7,599.50 0% | 11.8% | Mex$8,341.93 | Mex$4,735.16 | n/a | 13 |
Aug ’23 | Mex$6,890.00 | Mex$7,529.84 +9.3% | 10.9% | Mex$8,186.69 | Mex$4,870.56 | n/a | 13 |
Jul ’23 | Mex$6,542.39 | Mex$7,091.56 +8.4% | 10.8% | Mex$7,731.45 | Mex$4,599.73 | Mex$7,050.03 | 13 |
Jun ’23 | Mex$6,368.00 | Mex$7,077.81 +11.1% | 10.9% | Mex$7,774.23 | Mex$4,625.18 | Mex$6,864.91 | 13 |
May ’23 | n/a | Mex$6,587.39 0% | 12.9% | Mex$7,573.95 | Mex$4,746.34 | Mex$6,543.00 | 13 |
Apr ’23 | Mex$6,123.50 | Mex$6,157.83 +0.6% | 9.3% | Mex$6,925.60 | Mex$4,786.81 | n/a | 13 |
Analyst Forecast: Target price is less than 20% higher than the current share price.